Kineta Inc (KANT) USD0.001

Sell:$0.33Buy:$0.33$0.07 (17.46%)

Prices delayed by at least 15 minutes
Sell:$0.33
Buy:$0.33
Change:$0.07 (17.46%)
Prices delayed by at least 15 minutes
Sell:$0.33
Buy:$0.33
Change:$0.07 (17.46%)
Prices delayed by at least 15 minutes

Company Information

About this company

Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.

Key people

Shawn P. Iadonato
Chairman of the Board
Craig W. Philips
President, Company Secretary
Keith A. Baker
Chief Financial Officer
Thierry Guillaudeux
Chief Scientific Officer
David A. Arkowitz
Independent Director
Raymond Bartoszek
Independent Director
Kimberlee Cobleigh Drapkin
Independent Director
Scott J. Dylla
Independent Director
Marion R. Foote
Independent Director
Click to see more

Key facts

  • EPIC
    KANT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US49461C1027
  • Market cap
    $4.24m
  • Employees
    4
  • Shares in issue
    12.27m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.